|| Checking for direct PDF access through Ovid
The tripeptide, tyroservatide (YSV), has been previously shown to have antitumor effects through unknown mechanism. In the current study, we examined whether YSV modulates the protumorigenic PI3K pathway in human BEL-7402 hepatocarcinoma cells. BEL-7402 hepatocarcinoma was transplanted into the subcutaneous tissues of nude mice, and YSV, at varying doses, was administered. RT-PCR and Western blot were used to analyze the expression of PTEN, AKT, p21 and p27. YSV at doses of 80 μg/kg/day, 160 μg/kg/day and 320 μg/kg/day markedly inhibited the growth of human BEL-7402 hepatocarcinoma (p< 0.05). YSV increased mRNA and protein expression of the tumor-suppressor genes,PTEN, p21andp27, and inhibited the mRNA and protein expression of the oncogeneAKT. Furthermore, YSV administration was associated with dephosphorylation of both PTEN (which activates PTEN) and AKT (which inhibits AKT). These results are consistent with the possibility that YSV mediates inhibition of tumor growth through inhibition of the PI3K pathway and suggests that YSV should be explored for use as an antitumor agent for hepatocarcinoma.